Gennao Bio Presents New Data on Novel Gene Monoclonal Antibody Platform Technology at the American Association for Cancer Research (AACR) 2021 Annual Meeting
April 10, 2021 08:30 ET | Gennao Bio
~ Preclinical data show the utility of Gennao’s proprietary first-in-class monoclonal antibody 3E10-D31N (GMABD31N), a cell penetrating antibody, to non-covalently bind to and systemically deliver...
Teneobio Announces Achievement of Milestone Payment as Janssen Advances Phase I Study of Bispecific JNJ-75348780 for the Treatment of NHL and CLL
April 05, 2021 08:00 ET | TeneoBio, Inc
NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies,...
teräcero round logo rbg 600.png
A new stage in COVID-19 testing – Teracero Pharma reports receiving the first authorization for a COVID-19 serology rapid test under the Minister of Health’s Interim Order
March 17, 2021 14:00 ET | Teracero Pharma Inc.
nal von Minden GmbH’s NADAL COVID-19 IgG/IgM Test is highly sensitive and specific to antibodies against SARS-CoV-2, requires no special training, and can provide results within 10 minutes MONTREAL,...
Teracero Pharma annonce avoir reçu la première autorisation au Canada en vertu de l'arrêté d’urgence du ministre de la Santé pour un test sérologique rapide pour la COVID-19
March 17, 2021 14:00 ET | Teracero Pharma Inc.
Le test NADAL COVID-19 IgG/IgM de nal von Minden GmbH est très sensible et spécifique aux anticorps contre le SRAS-CoV-2, ne nécessite aucune formation particulière et fournit des résultats en 10...
Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer
February 11, 2021 07:30 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Lee’s Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation in China for the Treatment of Recurrent or Metastatic Cervical Cancer
February 09, 2021 09:00 ET | Sorrento Therapeutics, Inc.
Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee’s Pharma.China National Medical Products Administration (NMPA) grants breakthrough Therapy...
Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada
February 09, 2021 07:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
PRPO logo.png
Precipio Launches COVID-19 Antibody Testing at Point-of-Care
January 28, 2021 09:30 ET | Precipio, Inc.
NEW HAVEN, Conn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that following receipt of an Emergency Use Authorization from the FDA...
Beroni Logo @ Dec 2019.png
Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) Received CE Certification
December 21, 2020 08:30 ET | Beroni Group Limited
NEW YORK and SYDNEY, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise focused on the...
Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19
December 10, 2020 08:30 ET | Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase...